A. Delacourte, Les diagnostics de la maladie d'Alzheimer, Annales de Biologie Clinique, vol.56, pp.133-174, 1998.

G. Mc-khann, D. Drachman, M. Folstein, R. Katzman, D. Price et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, issue.7, pp.939-983, 1984.
DOI : 10.1212/WNL.34.7.939

A. Delacourte and L. Buee, Normal and Pathological Tau Proteins as Factors for Microtubule Assembly, Jnt Rev Cytol, vol.171, pp.167-224, 1997.
DOI : 10.1016/S0074-7696(08)62588-7

J. Ankri, Diagnostic, ln: Ankri J. La maladie d'Alzheimer, pp.53-64, 2000.

J. Kang, L. Hg, and A. Unterbeck, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, vol.325, issue.6106, pp.733-739, 1987.
DOI : 10.1038/325733a0

J. Hardy, Amyloid, the presenilins and Alzheimer's disease, Trends in Neurosciences, vol.20, issue.4, pp.154-163, 1997.
DOI : 10.1016/S0166-2236(96)01030-2

W. Strittmatter and A. Roses, Apolipoprotein E and Alzheimer disease., Proceedings of the National Academy of Sciences, vol.92, issue.11, pp.4-725, 1995.
DOI : 10.1073/pnas.92.11.4725

M. Colle, F. Dessi, C. Duyckaerts, and J. Hauw, Lésions cérébrales, hypothèses pathogéniques et étiologiques de la maladie d' Alzheimer, La revue du praticien, vol.48, pp.1873-1877, 1998.

G. Schellenberg, S. Deeb, and M. Boehnke, Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type, Journal of Neurogenetics, vol.140, issue.2, pp.97-108, 1987.
DOI : 10.1192/bjp.140.3.249

W. Strittmater, A. Saunders, and D. Schmechel, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease., Proceedings of the National Academy of Sciences, vol.90, issue.5, pp.1977-81, 1993.
DOI : 10.1073/pnas.90.5.1977

D. Campion, A. Brice, and D. Hannequin, Les facteurs génétiques dans l'étiologie de la maladie d' Alzheimer. Médecine/sciences l 996, pp.723-754
DOI : 10.4267/10608/813

P. Amoyel, T. Brousseau, and M. Chartier-halin, Mutations du gène de l' ApoE et maladie d' Alzheimer Alpha 2 macroglobuline et polymorphisme du promoteur de l 'ApoE : nouveaux marqueurs de la maladie d' Alzheimer sporadique tardive, Rev Neurol Rev Neurol, vol.155, issue.3, pp.3-21, 1999.

Y. Agid, A. Brice, and D. Campion, Génétique de la maladie d' Alzheimer, Rev Neurol, vol.154, pp.2-65, 1998.

M. Mattson, Alzheimer et stress oxydatif, Actualités Innovation Médecine, vol.54, pp.41-48, 1998.

Q. Guo, Les mutations de la préséniline sensibilisent les neurones à la suppression du facteur trophique et à l'exposition à la j3A, Journal Of Neuroscience, vol.17, pp.4212-4234, 1997.

F. Checler, N. Chevallier, and C. Drouot, Stratégies d'identification des sécrétases impliquées dans la maladie d'Alzheimer, Annales de Biologie Clinique, vol.3, pp.277-84, 1998.

I. Saitoh, T. Sundsmo, M. Roch, and J. , Secreted form of amyloid ?? protein precursor is involved in the growth regulation of fibroblasts, Cell, vol.58, issue.4, pp.615-637, 1989.
DOI : 10.1016/0092-8674(89)90096-2

Y. Suh, An Etiological Role of Amyloidogenic Carboxyl-Terminal Fragments of the ??-Amyloid Precursor Protein in Alzheimer's Disease, Journal of Neurochemistry, vol.68, issue.5, pp.1781-91, 1997.
DOI : 10.1046/j.1471-4159.1997.68051781.x

M. Citron, T. Diehl, G. Gordon, A. Biere, P. Seubert et al., Evidence that the 42- and 40-amino acid forms of amyloid ?? protein are generated from the ??-amyloid precursor protein by different protease activities, Proceedings of the National Academy of Sciences, vol.3, issue.1, pp.13170-13175, 1996.
DOI : 10.1006/nbdi.1996.0003

K. Sweadner, /. Isozymes-of-the-na+, and . K+-atpase, Isozymes of the Na+/K+-ATPase, Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, vol.988, issue.2, pp.185-220, 1989.
DOI : 10.1016/0304-4157(89)90019-1

E. Carafoli, The Ca 2 + pump of the plasma membrane, J Biol Chem, vol.4, pp.2115-2123, 1992.

W. Wood, U. Igbavboa, A. Rao, F. Schroeder, and N. Avdulov, Cholesterol oxidation reduces Ca2+ + Mg2+-ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes, Brain Research, vol.683, issue.1, pp.36-42, 1995.
DOI : 10.1016/0006-8993(95)00347-S

M. Mattson, K. Tomaselli, and R. Rydel, Calcium-destabilizing and neurodegenerative effects of aggregated ??-amyloid peptide are attenuated by basic FGF, Brain Research, vol.621, issue.1, pp.35-49, 1993.
DOI : 10.1016/0006-8993(93)90295-X

M. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg et al., f3 amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity, J Neurosci, vol.12, pp.376-89, 1992.

J. Koj, L. Yang, and C. Cotman, f3 amyloid protein increases the vulnerability of cultured cortical neurons to excititoxic damage, Brain Res, vol.533, pp.315-335, 1990.

M. Shearman, S. Hawtin, and V. Tailor, The Intracellular Component of Cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction Is Specifically Inhibited by ??-Amyloid Peptides, Journal of Neurochemistry, vol.65, issue.1, pp.218-245, 1995.
DOI : 10.1046/j.1471-4159.1995.65010218.x

R. Kalaria and S. Harik, Reduced Glucose Transporter at the Blood-Brain Barrier and in Cerebral Cortex in Alzheimer Disease, Journal of Neurochemistry, vol.262, issue.4, pp.1083-1088, 1992.
DOI : 10.1001/archneur.1985.04060100083029

Z. Khachaturian, Diagnosis of Alzheimer's Disease, Archives of Neurology, vol.42, issue.11, pp.1097-105, 1985.
DOI : 10.1001/archneur.1985.04060100083029

S. Mirra, M. Gearing, and D. Mckeel, Interlaboratory Comparison of Neuropathology Assessments in Alzheimer??s Disease, Journal of Neuropathology and Experimental Neurology, vol.53, issue.3, pp.303-318, 1994.
DOI : 10.1097/00005072-199405000-00012

M. Mattson, Cellular actions of f3-amyloid precursor protein and its soluble and fibrillogenic peptides derivatives, Physiological Revieuws, vol.77, pp.1081-132, 1997.

J. Geddes and M. Mattson, The aging brain. Greenwich CT, 1997.

C. Behl, J. Davis, R. Lesley, and D. Schubert, Hydrogen peroxide mediates amyloid ?? protein toxicity, Cell, vol.77, issue.6, pp.817-844, 1994.
DOI : 10.1016/0092-8674(94)90131-7

D. Butterfield, K. Hensly, M. Harris, M. Mattson, and J. Carney, ??-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer???s Disease, Biochemical and Biophysical Research Communications, vol.200, issue.2, pp.710-715, 1994.
DOI : 10.1006/bbrc.1994.1508

I. , J. Carney, and A. , Role of protein oxidation in aging and in ageassociated neurodegenerative disease, Lift Sei, vol.55, pp.2097-103, 1994.

C. Pike, D. Burdick, A. Walencewicz, C. Glabe, and C. Cotman, Neurodegeneration induced by f3-amyloid peptides in vitro : the role of peptide assembly state, J Neurosci, vol.13, pp.1676-87, 1993.

T. Dyrks, E. Dyrks, T. Hartmann, C. Masters, and K. Beyreuther, Amyloidogenicity of f3 A4 and f3A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation, J Bio! Chem, vol.267, pp.18210-18217, 1992.

M. Aksenova, D. Butterfield, and J. Carney, A mode! for f3-amyloid agregation and neurotoxicity based on free radical generation by the peptide : relevance to Alzheimer's disease, Proc Nat! Acad Sei, vol.91, pp.3270-3274, 1994.

D. Attwell, B. Miller, M. Sarantis, and F. Traynelis, Potentation of NMDA receptor currents by arachidonic acid, Nature, vol.355, pp.722-727, 1992.

D. Beher, K. Beyreuther, and L. Hesse, Reactive oxygen species and Alzheimer's disease, Biochemical Pharmacology, vol.54, pp.533-542, 1997.

P. Bozner, Y. Chyan, and K. Hsiao, Evidence of oxydative stress and in vivo neurotoxicity of f3-amyloid in a transgenic mouse mode! of Alzheimer's disease, AmericanJournal Of Pathology, vol.152, pp.871-877, 1998.